| DC48921 |
Benzomalvin B |
Benzomalvin B is the less active analogs of Benzomalvin A. Benzomalvin B is weakly active against substance P. |
|
| DC48933 |
TP-16 |
TP-16 is a novel and selective EP4 antagonist with an IC50 of 2.1 nM. |
|
| DC48934 |
EP2 receptor antagonist-1 |
EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effects. |
|
| DC48970 |
ONO-8713 |
ONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist. |
|
| DC48979 |
TASP0390325 |
TASP0390325 is a high affinity and orally active arginine vasopressin receptor 1B (V1B receptor) antagonist with antidepressant and anxiolytic activities. |
|
| DC48983 |
Ifetroban |
Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity. |
|
| DC48998 |
Verlukast |
Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma. |
|
| DC49001 |
PG01037 dihydrochloride |
PG01037 (dihydrochloride) is a potent and selective dopamine D3 receptor antagonist with a Ki of 0.7 nM. |
|
| DC49010 |
RS 39604 |
RS 39604 is a potent, selective, and orally active 5-HT4 receptor antagonist with a pKi of 9.1 in guinea pig striatal membranes. RS 39604 displays a low affinity (pKi<6.5) for 5-HT1A, 5-HT2C, 5-HT3, α1c, D1, D2, M1, M2, AT1, B1 and opioid mu receptors and moderate affinity for δ1, (pKi=6.8) and δ2 (pKi=7.8) sites. |
|
| DC49032 |
AZ-GHS-22 |
AZ-GHS-22 is a potent, non-CNS penetrant GHS-R1a inverse agonist (IC50=0.77 nM). |
|
| DC49039 |
AF-DX 384 |
AF-DX 384 is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine. |
|
| DC49050 |
GPR84 antagonist 2
Featured
|
GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC50=8.95 nM). |
|
| DC49057 |
CCG258747 |
CCG258747 is a selective GRK2 inhibitor (IC50=18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, >5500, and >550–fold, respectively).CCG258747 also blocks the internalization of the µ-opioid receptor. G protein-coupled receptor (GPCR) kinases (GRKs) are attractive targets for the research of heart failure. |
|
| DC49073 |
Ablukast |
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is LTD4 receptor antagonist. |
|
| DC49084 |
Lubabegron |
Lubabegron is a potent modulator of β-adrenergic receptor (β -AR). Lubabegron demonstrates antagonistic behavior at the β1 and β 2 receptor subtypes and agonistic behavior at the β 3 receptor subtype in cattle. Lubabegron reduces NH3 gas emissions from an animal or its waste. |
|
| DC49124 |
GLP-1 receptor agonist 7 |
GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b). |
|
| DC49131 |
GLP-1 receptor agonist 9 |
GLP-1 receptor agonist 9 is a GLP-1 receptor agonist, example 7, extracted from WO2020234726 A1. |
|
| DC49133 |
SSTR5 antagonist 2 hydrochloride |
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM). |
|
| DC49156 |
Peptide YY (PYY) (3-36), Human |
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion. |
|
| DC49157 |
GLP-1 receptor agonist 8 |
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17). |
|
| DC49208 |
PROTAC(H-PGDS)-7 |
PROTAC(H-PGDS)-7 is a Hematopoietic prostaglandin D synthase (H-PGDS) PROTAC degrader, with a DC50 of 17.3 pM. |
|
| DC49220 |
L-Glutamine-1-13C |
L-Glutamine-1-13C (L-Glutamic acid 5-amide-1-13C) is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells. |
|
| DC49221 |
L-Glutamine-5-13C |
L-Glutamine-5-13C (L-Glutamic acid 5-amide-5-13C) is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells. |
|
| DC49271 |
BIM-26226
Featured
|
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer. |
.gif)
|
| DC49310 |
L-Glutamine-15N2 |
L-Glutamine-15N2 (L-Glutamic acid 5-amide-15N2) is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells. |
|
| DC49315 |
L-Glutamine-15N-1 |
L-Glutamine-15N-1 (L-Glutamic acid 5-amide-15N-1) is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells. |
|
| DC49331 |
4-Methylhistamine dihydrochloride |
4-Methylhistamine (dihydrochloride) is the potent agonist of histamine 4 receptor (H4R). 4-Methylhistamine (dihydrochloride) has the potential for the research of immune-related diseases such as cancer and autoimmune disorders. |
|
| DC49332 |
(R)-(-)-α-Methylhistamine dihydrochloride |
(R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM. (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats. |
|
| DC49342 |
A6770 |
A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [3H]dhS1P increase. |
|
| DC49365 |
Zendusortide |
Zendusortide is a sortilin binding peptide. |
|
